FermenGIN® – Bioavailable Ginsenoside, Powered by Bioconversion

FermenGIN® is a bioconverted Korean red ginseng extract designed to unlock the bioavailability of key ginsenosides. While the conversion and absorption of conventional ginseng can vary depending on an individual’s gut microbiome, FermenGIN uses enzymatic bioconversion to produce more readily absorbed minor ginsenosides, including F2 and Compound K, before consumption.

Human pharmacokinetic research demonstrates significantly greater systemic exposure to key ginsenosides compared with conventional red ginseng.

FermenGIN also utilizes γ-cyclodextrin microencapsulation technology to help reduce the characteristic bitterness of ginseng resulting in a more formulation-friendly sensory profile and improved bioavailability.

Backed by human and preclinical research, comprehensive safety testing, a 3-year shelf life, and US FDA NDI Notification No. 1362, FermenGIN provides a science-backed approach to delivering bioavailable ginsenosides for modern supplement and functional product formulations.